抗线粒体抗体M2亚型检测的经济价值研究

摘要

Objective:To increase the detection rate of primary biliary cirrhosis(PBC)through testing anti-mitochondrial antibody-M2(AMA-M2)and to evaluate the economic value of the indication. Methods:Cost-effectiveness method was used to measure the economic value of screening PBC patients with AMA-M2 regionally and nationally. Results:Early screening of AMA-M2 in patients with PBC could bring extraordinary economic benefits to patients and the society from both direct medical costs and life value perspective. Conclusion:It is suggested that AMA-M2 should be enrolled as one of the routine indexes of health examination in China,which is an important way to increase PBC detection rate and decrease treatment cost.%目的：通过在体检人群中筛查抗线粒体抗体M2亚型（anti-mitochondrial antibody-M2，AMA-M2）以期提高原发性胆汁性肝硬化（PBC）的检出率，并评估该指标普查的经济价值。方法：运用卫生经济学中的成本效益法，测算区域性及全国性通过AMA-M2筛查PBC患者的经济效益。结果：无论在直接的医疗成本还是生命年价值上，通过AMA-M2早期筛查PBC将对患者及社会带来巨大的经济效益。结论：将AMA-M2检测作为我国常规健康体检筛查指标是提高PBC检出率并降低治疗成本的重要途径。